Drugs / BIA 5-453
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03014375 | Sep → Oct 2008 | congestive heart failure, hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03099226 | Jul 2008 → Apr 2009 | hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03090568 | Jul → Aug 2008 | congestive heart failure, hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03090724 | Jun → Aug 2008 | heart failure, hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02840565 | Sep 2007 → Jul 2008 | heart failure, hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02845037 | May → Sep 2007 | heart failure, hypertensive disorder | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIA 5-453 | “Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).” NCT03014375 ↗ |
| Action | Inhibit | “Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453” NCT02845037 ↗ |
| Route | Oral | “for oral administration” NCT02840565 ↗ |